Regional Anesthesia & Pain Medicine: first published as 10.1097/AAP.0000000000000807 on 1 July 2018. Downloaded from http://rapm.bmj.

com/ on November 1, 2021 by guest.

ERRATUM

Regional Anesthesia in the Patient Receiving Antithrombotic

or Thrombolytic Therapy: American Society of Regional
Anesthesia and Pain Medicine Evidence-Based Guidelines
(Fourth Edition): Erratum

T he last name of author Erik Vandermeulen was misspelled in the recent article that appeared in the April 2018 issue: Regional Anes-
thesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medi-
cine Evidence-Based Guidelines (Fourth Edition). In addition, the following errors have been noted in the text:
Recommendation 3.4.1 on page 272 is a new recommendation. The Remarks following the recommendation should read: “This is a
new recommendation. Earlier guidelines did not specify a time interval between SC administration of UFH and neuraxial blockade. These
recommendations are based on the pharmacology of SC 5000-U dose of UFH, which results in a significant anticoagulant effect that per-
sists 4 to 6 hours after administration.”
Recommendation 3.4.4 on page 272 should be corrected to read: “Recommendation 3.4.4 Postoperative low-dose UFH. There is no
contraindication to maintaining neuraxial catheters in the presence of low-dose UFH. We suggest catheter removal occur 4 to 6 hours after
heparin administration. Subsequent heparin administration may occur immediately after neuraxial blockade or catheter removal (grade 2C).
Remarks: This recommendation has been updated. Previously a 1-hour time interval was recommended between neuraxial blockade or
catheter removal and administration of low-dose SC UFH. These recommendations were based on the pharmacology of SC 5000-U dose
of UFH, which does not result in a significant anticoagulant effect for least 1 hour after administration.”
Recommendation 13.5 on page 286 should state “13.5 Platelet GP IIb/IIIa. The platelet GP IIb/IIIa inhibitors exert a profound effect
on platelet aggregation. Following administration, the time to normal platelet aggregation is 24 to 48 hours for abciximab and 4 to 8 hours
for eptifibatide and tirofiban.”

Protected by copyright.
REFERENCE
Horlocker TT, Vandermeuelen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT. Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic
Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition). Reg Anesth Pain Med. 2018;43:263–309.

566 Regional Anesthesia and Pain Medicine • Volume 43, Number 5, July 2018

Copyright © 2018 American Society of Regional Anesthesia and Pain Medicine. Unauthorized reproduction of this article is prohibited.